肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2014年
5期
336-338,341
,共4页
晚期胃癌%威麦宁胶囊%奥沙利铂%卡培他滨
晚期胃癌%威麥寧膠囊%奧沙利鉑%卡培他濱
만기위암%위맥저효낭%오사리박%잡배타빈
Advanced gastric cancer%Weimaining capsule%Oxaliplatin%Capecitabine
目的 评价威麦宁胶囊联合XELOX(卡培他滨+奥沙利铂)方案治疗晚期胃癌的疗效及安全性.方法 62例符合入组条件的晚期胃癌患者按随机数字表法随机分为观察组和对照组.观察组31例患者接受威麦宁胶囊和XELOX方案全身化疗,对照组31例患者仅接受同等剂量强度的XELOX方案化疗,21 d为1个周期,每例患者至少接受2个周期治疗,每2个周期治疗后评价疗效.结果 观察组的中位疾病进展时间(TTP)为5.5个月,对照组为4.8个月,二组间差异无统计学意义(P=0.238).观察组疾病控制率(DCR)较对照组提高[67.7％(21/31)比41.9％(13/21),P＜ 0.05];两组客观有效率(ORR)差异无统计学意义[32.3％(10/31)比25.8％(8/31),P＞0.05].所有患者均未发生Ⅴ级不良反应(即因药物导致死亡).观察组Ⅱ～Ⅳ级中性粒细胞下降发生率及Ⅱ～Ⅳ级恶心、呕吐发生率均较对照组低[16.13％(5/31)比38.71％(12/31),P＜0.05;12.90％(4/31)比35.48％(11/31),P＜0.05],其他不良反应两组间差异无统计学意义(P＞0.05).结论 威麦宁胶囊联合XELOX方案治疗晚期胃癌可显著提高DCR并减轻部分患者化疗不良反应,安全性良好,值得临床推广应用.
目的 評價威麥寧膠囊聯閤XELOX(卡培他濱+奧沙利鉑)方案治療晚期胃癌的療效及安全性.方法 62例符閤入組條件的晚期胃癌患者按隨機數字錶法隨機分為觀察組和對照組.觀察組31例患者接受威麥寧膠囊和XELOX方案全身化療,對照組31例患者僅接受同等劑量彊度的XELOX方案化療,21 d為1箇週期,每例患者至少接受2箇週期治療,每2箇週期治療後評價療效.結果 觀察組的中位疾病進展時間(TTP)為5.5箇月,對照組為4.8箇月,二組間差異無統計學意義(P=0.238).觀察組疾病控製率(DCR)較對照組提高[67.7％(21/31)比41.9％(13/21),P＜ 0.05];兩組客觀有效率(ORR)差異無統計學意義[32.3％(10/31)比25.8％(8/31),P＞0.05].所有患者均未髮生Ⅴ級不良反應(即因藥物導緻死亡).觀察組Ⅱ～Ⅳ級中性粒細胞下降髮生率及Ⅱ～Ⅳ級噁心、嘔吐髮生率均較對照組低[16.13％(5/31)比38.71％(12/31),P＜0.05;12.90％(4/31)比35.48％(11/31),P＜0.05],其他不良反應兩組間差異無統計學意義(P＞0.05).結論 威麥寧膠囊聯閤XELOX方案治療晚期胃癌可顯著提高DCR併減輕部分患者化療不良反應,安全性良好,值得臨床推廣應用.
목적 평개위맥저효낭연합XELOX(잡배타빈+오사리박)방안치료만기위암적료효급안전성.방법 62례부합입조조건적만기위암환자안수궤수자표법수궤분위관찰조화대조조.관찰조31례환자접수위맥저효낭화XELOX방안전신화료,대조조31례환자부접수동등제량강도적XELOX방안화료,21 d위1개주기,매례환자지소접수2개주기치료,매2개주기치료후평개료효.결과 관찰조적중위질병진전시간(TTP)위5.5개월,대조조위4.8개월,이조간차이무통계학의의(P=0.238).관찰조질병공제솔(DCR)교대조조제고[67.7％(21/31)비41.9％(13/21),P＜ 0.05];량조객관유효솔(ORR)차이무통계학의의[32.3％(10/31)비25.8％(8/31),P＞0.05].소유환자균미발생Ⅴ급불량반응(즉인약물도치사망).관찰조Ⅱ～Ⅳ급중성립세포하강발생솔급Ⅱ～Ⅳ급악심、구토발생솔균교대조조저[16.13％(5/31)비38.71％(12/31),P＜0.05;12.90％(4/31)비35.48％(11/31),P＜0.05],기타불량반응량조간차이무통계학의의(P＞0.05).결론 위맥저효낭연합XELOX방안치료만기위암가현저제고DCR병감경부분환자화료불량반응,안전성량호,치득림상추엄응용.
Objective To evaluate the efficacy and safety of the combination of Weimaining capsule and XELOX regimen (oxaliplatin plus capecitabine) in the treatment of advanced gastric cancer patients.Methods A total of 62 patients with advanced gastric cancer who fulfilled all predetermined criteria were randomly divided into observation group and control group.The 31 patients in observation group received a combination of Weimaining capsule and XELOX regimen,the 31 patients in control group received only XELOX regimen at the same dose intensity.Each patient received at least two cycles (1 cycle =21 days) of treatment,the efficacy was assessed after two cycles.Results The median time-to-progression (TTP) of observation and control groups were 5.5 and 4.8 months,respectively.The difference had no statistical significance (P =0.238).The disease control rates (DCR) of observation group was significantly improved compared with control group [67.7 ％ (21/31) vs 41.9 ％ (13/21),P ＜ 0.05],the difference was statistically significant,while the objective response rate (ORR) of the 2 groups had no statistical difference [(32.3 ％ (10/31) vs 25.8 ％ (8/31),P ＞ 0.05].In drug safety aspects,there was no Ⅴ grade adverse reactions (deaths caused by drug) among all the patients.Rates of grades Ⅱ-Ⅳ neutrocytopenia and nausea,vomiting in observation group were obviously lower than control group [16.13 ％ (5/31) vs 38.71％ (12/31),P ＜ 0.05;12.90 ％ (4/31) vs 35.48 ％ (11/31),P ＜ 0.05],other adverse reactions between the 2 groups had no statistical difference.Conclusions A combination of Weimaining capsule and XELOX regimen in the treatment of advanced gastric cancer patients can improve DCR significantly and reduce part of adverse reaction induced by chemotherapy with satisfactory safety.This method is worthy of application widely.
